ABSTRACT
OBJECTIVE Taxane based chemotherapy agents such as docetaxel and paclitaxel are used for a wide range of cancers. Although much has been published on adverse events related to taxanes, data on ocular outcomes with these very important drugs is scant. We sought to quantify the risk of three ocular adverse events: 1) epiphora, 2) cystoid macular edema (CME) and 3) optic neuropathy with taxane based chemotherapy agents by undertaking a large pharmacoepidemiologic study.
DESIGN New users, retrospective cohort study design
SUBJECTS, PARTICIPANTS, CONTROLS We created a cohort of new users of women matched by age (within one year) on docetaxel or paclitaxel and new users of tamoxifen as controls. Study members were followed to the first incidence of the three outcomes.
METHODS Descriptive statistics were used to examine demographics of the exposed and unexposed groups. A Cox model was constructed to compute crude and adjusted hazard ratios. Potential confounders for each outcome were adjusted for.
MAIN OUTCOME MEASURES First diagnosis of 1) epiphora, 2) cystoid macular edema (CME) or 3) optic neuropathy ascertained using international classification for diseases 9th or 10th division codes.
RESULTS For the epiphora analysis there were 1,824 taxane users (PTX or DTX) and 16,395 tamoxifen users. The crude HR for this association was 7.32 (95%CI: 4.25-16.61) and adjusted HR was 5.15 (95% CI:2.79-9.54). For the CME analysis there were 1,909 taxane user and 16,524 tamoxifen users. The crude HR for CME comparing taxane users to tamoxifen users was 1.37 (95% CI: 0.72-2.60) and adjusted HR was 1.33 (95% CI: 0.70-2.53). For optic neuropathy there were 1,913 taxane users and 16,566 tamoxifen users. The crude HR was 4.43 (95% CI:1.10-17.82) and the adjusted HR was 4.44 (95% CI:1.04-18.87). When we restricted our analysis to only cases of toxic optic neuropathy the aged-matched HR remained elevated (HR=7.24, 95% CI: 1.13-46.36).
CONCLUSION In a cohort of women who were using taxane chemotherapy agents, there was an elevated risk for epiphora, optic neuropathy and a less precise increase in risk for cystoid macular edema. Ophthalmologists and oncologists should be aware of these adverse events in women with breast cancer who use these drugs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the University of British Columbia gave ethics approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding source: This study was funded by Department of Ophthalmology of UBC.
Conflicts of interest: None of the authors have any conflicts to report.
Data Availability
Data is available upon reasonable request as contained in the manuscript
